<?xml version="1.0" encoding="UTF-8"?>
<fn-group>
 <fn id="d33e1118">
  <p id="ntpara0010">Drs Rosenbach and Merola contributed equally to the manuscript development (cosenior authors).</p>
 </fn>
 <fn id="d33e1121">
  <p id="ntpara0015">Funding sources: None.</p>
 </fn>
 <fn id="d33e1124">
  <p id="ntpara0020">Conflicts of interest: Dr Niaki has participated in an advisory board for Eli Lilly. Dr Anadkat is currently serving as consultant for Boehringer-Ingelheim, NovoCure, and OnQuality and as an investigator for Biogen, Lutris, AnaptyxBio, Boehringer-Ingelheim, OnQuality, Norvartis, ChemoCentryx, UCB Biopharma, and XBiotech. Dr Shinohara has been a principle investigator for clinical trials (Actelion, Soligenix, MiRAGEN). Dr Rosenbach, has served as a consultant for Merck, aTyr, Processa, and Janssen and has received research support from 
   <funding-source id="gs1">Processa</funding-source> and salary support from 
   <italic>JAMA Dermatology</italic>. Dr Merola is a consultant and/or investigator for Merck, Bristol-Myers Squibb, AbbVie, Dermavant, Eli Lilly, Novartis, Janssen, UCB, Celgene, Sanofi, Regeneron, Arena, Sun Pharma, Biogen, Pfizer, EMD Sorono, Avotres, and LEO Pharma. Drs Chen, Fox, Harp, Micheletti, Nambudiri, and Pasieka have no conflicts of interest to declare.
  </p>
 </fn>
 <fn id="d33e1132">
  <p id="ntpara0025">IRB approval status: Not required.</p>
 </fn>
 <fn id="d33e1135">
  <p id="ntpara0075">Reprints not available from the authors.</p>
 </fn>
</fn-group>
